Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alba Therapeutics has begun testing AT-1001, an orally administered zonulin receptor antagonist that is being developed for the treatment of celiac disease.
Subscribe to our email newsletter
Celiac disease is an auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten.
The only treatment presently available for the condition is complete elimination of gluten from the diet, which results in remission for some patients.
According to the National Institutes of Health (NIH), celiac disease affects approximately three million Americans, although the diagnosis is rarely made.
The double blind, placebo controlled dose escalation study will evaluate the safety, tolerability and pharmacokinetics of AT-1001 and is being conducted in twenty-four normal volunteers.
“The data we plan to generate from this and subsequent phase I studies will educate us on the safety and tolerability of AT-1001, in addition to quantifying the impact of this novel compound on intestinal permeability,” stated Dr Blake Paterson, CEO of Alba.